Detalles de la búsqueda
1.
Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
BMC Neurol
; 23(1): 311, 2023 Aug 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37644415
2.
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
Mult Scler
; 28(8): 1229-1238, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34787005
3.
A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries.
BMC Neurol
; 19(1): 5, 2019 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30616596
4.
A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.
J Neuroinflammation
; 15(1): 255, 2018 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30185189
5.
Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study.
BMC Neurol
; 17(1): 17, 2017 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28129749
6.
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
BMC Neurol
; 14: 21, 2014 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-24475777
7.
Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
Ann Neurol
; 71(5): 614-23, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22522477
8.
Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Mult Scler Relat Disord
; 79: 104938, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37769428
9.
Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions.
Mult Scler
; 18(12): 1782-90, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22492130
10.
Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.
J Neurol Neurosurg Psychiatry
; 82(9): 970-7, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21784757
11.
[Treatment of NMO].
Rinsho Shinkeigaku
; 49(11): 902-5, 2009 Nov.
Artículo
en Japonés
| MEDLINE | ID: mdl-20030244
12.
[Overview of MS: proposal of new MS definition/classification and review of the results of recent clinical trials].
Nihon Rinsho
; 66(6): 1081-6, 2008 Jun.
Artículo
en Japonés
| MEDLINE | ID: mdl-18540351
13.
Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody.
J Neurol Neurosurg Psychiatry
; 78(9): 990-2, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17702782
14.
[Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
Rinsho Shinkeigaku
; 47(7): 401-6, 2007 Jul.
Artículo
en Japonés
| MEDLINE | ID: mdl-17710882
15.
Safety and effectiveness of interferon ß-1a intramuscular therapy: results of the postmarketing drug surveillance in Japan.
Rinsho Shinkeigaku
; 57(10): 553-561, 2017 10 27.
Artículo
en Japonés
| MEDLINE | ID: mdl-28966229
16.
Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.
Neurol Ther
; 6(2): 197-211, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29119538
17.
Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis.
Neurol Ther
; 6(1): 153-159, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28078634
18.
Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
Mult Scler Relat Disord
; 11: 25-31, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28104251
19.
Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.
Neurol Ther
; 6(1): 39-55, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27921221
20.
Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord
; 7: 102-8, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27237769